Præsentationer og publikationer

​Det molekylære patologilaboratorium publicerer og præsenterer årligt en stor mængde forskningsresultater, mange med indsigt i og råd om hvordan man vælger de korrekte test til primær- og opfølgende screening for livmoderhalskræft.

Disagreement between Human Papillomavirus Assays: An Unexpected Challenge for the Choice of an Assay in Primary Cervical Screening. Rebolj M, Preisler S, Ejegod DM, Rygaard C, Lynge E, Bonde J. PLoS One. 2014 Jan 20;9(1):

Prevalence of Human Papillomavirus in 5,072 Consecutive Cervical SurePath Samples Evaluated with the Roche Cobas HPV Real-Time PCR Assay, Preisler, Sarah; Rebolj, Matejka; Untermann, Anette; et al. Source: PLOS ONE Volume: 8 Issue: Published: MAR 22 2013

Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in Denmark, Goldman, Bryan; Rebolj, Matejka; Rygaard, Carsten; et al. Vaccine, Vol. 31 Issue: 12 Pages: 1604 MAR 15 2013

Prevalence of Human Papillomavirus Infection in Unselected SurePath Samples Using the APTIMA HPV mRNA Assay, Rebolj, Matejka; Preisler, Sarah; Ejegod, Ditte M.; et al. Journal of molecular diagnostics Volume: 15 Issue, SEP 2013

"Prøv et privat/offentligt forskningssamarbejde"

Elsebeth Lynge, Carsten Rygaard, Matejka Rebolj, Jesper Bonde, Ugeskrift for læger, pp. 1474, 2012.

Human papillomavirus testing and genotyping in cervical screening. Rebolj M, Lynge E, Bonde J. Expert Rev Anticancer Ther. 2011 Jul;11(7):1023-31. Review.

Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. Rebolj M, Bonde J, Njor SH, Lynge E. BMJ. 2011, Review.
Redaktør